Childhood high-risk neuroblastomas with MYCN gene amplification are difficult to treat effectively 1 . This has focused attention on tumor-specific gene dependencies that underlie tumorigenesis and thus provide valuable targets for the development of novel therapeutics. Using unbiased genome-scale CRISPR-Cas9 approaches to detect genes involved in tumor cell growth and survival 2-6 , we identified 147 candidate gene dependencies selective for MYCN-amplified neuroblastoma cell lines, compared to over 300 other human cancer cell lines. We then used genome-wide chromatin-immunoprecipitation coupled to high-throughput sequencing analysis to demonstrate that a small number of essential transcription factors-MYCN, HAND2, ISL1, PHOX2B, GATA3, and TBX2are members of the transcriptional core regulatory circuitry (CRC) that maintains cell state in MYCN-amplified neuroblastoma. To disable the CRC, we tested a combination of BRD4 and CDK7 inhibitors, which act synergistically, in vitro and in vivo, with rapid downregulation of CRC transcription factor gene expression. This study defines a set of critical dependency genes in MYCN-amplified neuroblastoma that are essential for cell state and survival in this tumor.
lineage. Others have been reported to be involved in neural crest cell specification and neuroblastoma pathogenesis 1, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . This set of transcriptional regulatory genes is highly connected by putative protein-protein interactions in the STRING database 21 (Fig. 1b ). Representative dependency scores in MYCN-amplified neuroblastoma compared to other tumor cells are shown in Fig. 1c ,d for the genes HAND2 and ISL1, and for a subset of other genes with nucleic acid binding and/or transcription factor activities in Supplementary  Fig. 1 . Our results show that many transcription factor genes with selective dependency in MYCN-amplified neuroblastoma cells also displayed dependency in the two MYCN non-amplified cell lines studied so far, although additional MYCN non-amplified lines will need to be studied before firm conclusions can be drawn. We next performed transient small-interfering RNA (siRNA) knockdown targeting messenger RNAs that encode five transcription factor dependencies (HAND2, ISL1, PHOX2B, GATA3, and TBX2) to independently verify that these genes represent dependencies in MYCN-amplified neuroblastoma cell lines. Depletion of expression of these genes resulted in suppression of colony formation and induction of apoptosis (Fig. 1e,f and Supplementary Figs. 2 and 3) . Thus, MYCN-amplified neuroblastoma cells rely on a discrete set of genes that are either unique to, or only minimally shared with, other tumor types.
The gene dependencies we identified suggest that diverse sets of complex pathways are activated to support the viability of MYCNamplified neuroblastoma. Given the overrepresentation of transcription factor and nucleic acid binding activities among the 147 gene dependencies (Fig. 1a ), we hypothesized that these genes were specifically required for transcriptional regulation in neuroblastoma cells. Previous studies have demonstrated that lineage-specific differences in cell state during development are determined by tissue-specific CRC that may be subverted to drive malignant transformation 22, 23 . CRCs are formed by transcription factors assembled into positive, feed-forward autoregulatory loops that establish and maintain cell lineage and identity through their extended regulatory networks 24, 25 . CRC transcription factor genes are typically marked by extensive stretches of acetylation at histone H3-lysine 27 (H3K27ac), a genomic feature characteristic of high levels of gene Letters NATURe GeNeTICS expression, termed super-enhancers 26, 27 (Fig. 2a ). To investigate the relevance of a CRC framework to the dependency genes identified earlier, we performed chromatin-immunoprecipitation coupled to high-throughput sequencing (ChIP-seq) for H3K27ac in 5 MYCNamplified neuroblastoma cell lines, identifying a shared set of 77 genes associated with super-enhancers across all 5 cell lines ( Fig. 2b and Supplementary Table 2 ). As observed in the selective dependencies, the super-enhancer-associated genes in MYCN-amplified neuroblastoma cells were overrepresented among ontologies 9, 10 including nucleic acid binding (21%, P = 3.93 × 10 −3 ) and transcription factor activity or binding (22%, P = 4.29 × 10 −8 ). Examples of the H3K27ac signals of highly ranked transcription factor genes are shown in Fig. 2c and Supplementary Fig. 4 .
When these 77 super-enhancer-associated genes were compared with the 147 selective dependencies in MYCN-amplified neuroblastoma identified by the CRISPR-Cas9 screen, 11 of the superenhancer-associated genes were selective dependencies and 10 of 11 (91%) of these genes encoded transcription factors (Fig. 2d ). This represents 11 of 69 super-enhancer-associated genes targeted by specific single guide RNAs (15.9%, P = 1.11 × 10 −10 for enrichment), since 8 of the super-enhancer-associated genes were non-coding and were not targeted in the screen. To verify that these genes are FAM200B   RNF19A   BCAS3   METTL23   SLC30A9   TBX2  PHOX2A   ISL1   MYT1   ZRANB2   ZNF117   LDB1   PHOX2B  TADA1   TAF5L  GATA3   SMARCA4   ASCL1 HAND2
Fig. 1 | Genome-scale CRISPR-Cas9 screening identifies selective neuroblastoma gene dependencies enriched for transcription factors. a, Gene
ontology classification of terms associated with selective dependencies in neuroblastoma reveals enrichment for transcription factor activity or binding and nucleic acid binding proteins. n = 147 genes, 252 GO-slim molecular class assignments. P = 8.48 × 10 −3 nucleic acid binding, P = 6.78 × 10 −3 transcription factor activity or binding, by 1-sided Fisher exact test (adjusted using Benjamini-Hochberg correction) comparing the ontologies of dependencies to all assayed genes in the genome. b, STRING database analysis demonstrates that 25 of 30 transcription factor dependencies have putative protein-protein interactions. Edge widths correspond to the level of confidence in interactions (medium confidence STRING score 0.4; high confidence STRING score 0.7; highest confidence STRING score 0.9). Red nodes indicate transcription factors previously co-reported with neuroblastoma in a literature search. c,d, Representative scatter plots showing neuroblastoma relative dependency on HAND2 (c) and ISL1 (d) with P < 1 × 10 −9 by permutation testing, with n = 9 MYCN-amplified neuroblastoma cell lines compared to n = 330 non-neuroblastoma cancer cell lines. Y axis shows the gene's dependency rank in an individual cell line. X axis shows the gene's dependency score in each cell line. e,f, Colony formation assay at 10 d in BE2C (e) and Kelly (f) cells treated with two independent siRNAs targeting ISL1, PHOX2B, HAND2, GATA3, and TBX2. BE2C/Kelly siRNA(1) n = 7 (control), 3 (HAND2, ISL1, PHOX2B), 4 (GATA3), 6 (TBX2); BE2C/Kelly siRNA(2) n = 3 (control, HAND2, ISL1, PHOX2B), 6 (GATA3, TBX2) biologically independent samples; BE2C P < 0.05 for all transcription factors relative to control siRNAs by 2-sided t-test. Center values represent mean and error bars represent s.d.
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NATURe GeNeTICS expressed in primary human neuroblastomas, we examined the expression level of each super-enhancer-associated, CRISPR-Cas9 dependency nucleic acid binding or transcription factor gene in four primary neuroblastoma tumor expression datasets. The majority of the super-enhancer-associated CRISPR-Cas9 dependency genes exhibited high levels of expression in primary neuroblastomas as compared to multiple other types of primary tumors ( Supplementary Fig. 5 ) with LDB1 as an exception. Recent evidence has suggested the presence of two superenhancer-associated transcriptional networks controlling neuroblastoma cell state, one representing a multipotent neural crest cell-like or mesenchymal cell state (NCC/MES) and a second representing sympathoadrenal cells, referred to as a noradrenergic (NOR/ADRN) cell state 28, 29 . The majority of cell lines and low passage primary tumors, regardless of MYCN-amplification, displayed super-enhancers associated with this core group of transcription factors ( Supplementary Fig. 6a,b ). Furthermore, analysis of neuroblastoma cell lines subdivided by transcriptional network subtype demonstrated that these CRC transcription factors were also marked by super-enhancers, although to a lesser degree in the NCC/MES cell state. Analysis of all neuroblastoma cell lines in our genome-scale CRISPR-Cas9 screen demonstrated gene expression signatures consistent with either NOR/ADRN or NCC/MES cell states ( Supplementary Fig. 6c ). Expression of CRC transcription factor genes was elevated in both neuroblastoma subtypes compared to cell lines derived from other tumor types ( Supplementary  Fig. 6d ). Further, these five CRC transcription factors represented gene dependencies in nearly all neuroblastoma cell lines, regardless of MYCN-amplification status or NOR/ADRN and NCC/MES cell state, indicating a general requirement for these genes in regulating cell growth and survival in neuroblastoma ( Supplementary Fig. 6e ).
Given these findings, we hypothesized that the CRC responsible for specifying neuroblastoma cell fate is formed by these superenhancer-marked transcription factor dependencies. To test this hypothesis, we performed ChIP-seq in BE2C and Kelly cells with antibodies recognizing MYCN and five super-enhancer-regulated transcription factor dependencies. These data demonstrated that HAND2, ISL1, PHOX2B, GATA3, TBX2, and MYCN bind consensus DNA sequences adjacent to each other to form dense clusters of transcription factors comprising distinct 'epicentres' 30, 31 within their own enhancer regions ( Fig. 3a and Supplementary Fig. 7 ). These epicentres occupied discrete regions of open chromatin delineated by assay for transposase-accessible chromatin using sequencing (ATAC-seq). Binding of each transcription factor was preferentially found in gene enhancers containing enriched consensus binding motifs ( Supplementary Table 3 and Supplementary Fig. 8 ), suggesting that these transcription factors collectively regulate the expression of their own genes, and each of the other five transcription factors evaluable by ChIP, and form a feed-forward autoregulatory CRC. When overexpressed, MYCN is thought to bind active 
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promoter and enhancer elements throughout the genome, similar to the activities of MYC 32, 33 , resulting in amplified transcription that overcomes rate-limiting constraints on cell proliferation and survival. Genome-wide ChIP-seq analysis demonstrated that MYCN binds coordinately with other members of the CRC to regions of open chromatin marked by enhancers across the genome (Fig. 3b ), indicating that it may function as a CRC member or, alternatively, as a general transcriptional amplifier as has recently been reported 34 . Amplification of the MYCN gene raised the background signal of input DNA across the amplified region, precluding formal evaluation of CRC transcription factor binding to any potential MYCN enhancer ( Supplementary Fig. 9 ). Analysis demonstrated a nearly twofold statistical enrichment of binding of all five CRC transcription factors, with or without MYCN, to dependency genes (P < 0.01 for binding to dependency genes versus remainder of expressed genes in the CRISPR-Cas9 screen by two-sided Fisher's exact test). However, MYCN and these transcription factors are also present at genes that are not selective neuroblastoma dependencies.
To establish co-regulation of CRC component genes, we determined the gene expression levels by reverse transcription 
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NATURe GeNeTICS qPCR (RT-qPCR) after transient siRNA-mediated knockdown of each gene ( Fig. 3c and Supplementary Fig. 10 ). We observed decreased expression levels of all CRC transcription factors after knocking down each individual CRC gene. The impact of CRC transcription factor depletion on the super-enhancer landscape of the cell remains to be studied; however, these data implicate these genes and their encoded transcription factors in a feedforward autoregulatory mechanism that drives MYCN-amplified neuroblastoma (Fig. 3d ). Efforts to target aberrant transcriptional activity in tumors such as MYCN-amplified neuroblastoma have centered on agents that inhibit cyclin-dependent kinases and BET-bromodomain-dependent pathways that act as mediators of MYCN-driven initiation and elongation of transcription 35, 36 . Based on the feed-forward, autoregulatory CRC we have identified, we postulated that MYCN-amplified neuroblastoma cells could be targeted synergistically by combining JQ1 (BRD4 inhibitor) and THZ1 (CDK7 inhibitor). While treatment with JQ1 or THZ1 alone reduced the growth of Kelly and BE2C cells ( Fig. 4a ), combination treatment dramatically reduced cell numbers and induced apoptosis ( Fig. 4a and Supplementary  Fig. 11 ). Comparison of results after treatment with multiple concentrations of JQ1 and THZ1 alone and together demonstrated synergistic inhibition of viability of a panel of both MYCN-amplified and non-amplified neuroblastoma cell lines by the Chou-Talalay 
NATURe GeNeTICS combination index ( Fig. 4b and Supplementary Fig. 12 ) 37-39 . Next, we subcutaneously xenografted BE2C cells in nude mice and treated tumor-bearing mice with vehicle control, JQ1, THZ1, or the combination. In contrast to control and single agent-treated mice, combination inhibition with JQ1 and THZ1 led to reduced tumor progression and increased survival compared to either single agent alone without a substantial effect on animal weight ( Fig. 4c and Supplementary  Fig. 13 ). These data indicate that compounds disrupting transcriptional initiation and elongation can serve as a synergistically potent and effective method of tumor inhibition in MYCN-amplified neuroblastoma in vitro and in vivo.
To evaluate the effects of combination treatment on both CRC and global gene expression, we treated BE2C cells with a synergistic combination of JQ1 for 0, 1, 4, and 12 h, and performed gene expression analysis with spike-in controls. In comparison to the top 1% of highest expressed transcripts, CRC mRNA levels rapidly decreased in expression after 1 h of treatment ( Fig. 4d,e ). We observed that the majority of downregulated genes at 4 h of combined JQ1 and THZ1 treatment were bound by all CRC members, suggesting that they represent a network of genes directly regulated by the CRC (Supplementary Fig. 14) . By 12 h of treatment, the majority of all mRNA transcripts were downregulated, indicative of general transcriptional collapse. These results were confirmed by RT-qPCR analysis of expression levels of CRC and non-CRC member genes (ACTB, HPRT) in BE2C and Kelly cells ( Supplementary Fig. 15 ). The expression level of each of the six transcription factor genes was dramatically reduced by the combination of JQ1 and THZ1, with more limited effects noted with either drug alone. These results underscore the effects of JQ1 and THZ1 combination treatment in MYCN-amplified neuroblastoma, although the complete effects of combination transcriptional disruption remain to be elucidated.
Our findings identify a collection of genes representing diverse vulnerabilities in MYCN-amplified neuroblastoma, including the transcription factors that form an autoregulatory CRC specific for these cells. At least six of the transcription factors encoded by members of the dependency group belong to this CRC, each of which directly regulates the expression of its own gene as well as those encoding the other CRC transcription factors. This CRC also controls an extended regulatory network of genes, which we suggest contributes to initiation and maintenance of the transformed phenotype in MYCN-amplified neuroblastoma. We hypothesize that a similar set of transcription factors form a CRC in MYCN non-amplified neuroblastoma, due to reliance on high-level expression of MYC or MYCN in these tumors. Our results underscore the interconnected autoregulatory mechanisms underlying the expression and activity of CRC transcription factors. This dependence on transcriptional activity leads to the enhanced vulnerability of these cells to combinatorial targeting of key nuclear proteins that mediate transcriptional initiation and elongation. A subset of the selective dependencies that we have identified in this tumor probably reflect the consequences of transformation by the CRC, and it will be important to investigate these genes and the pathways they control as a source of additional 'druggable' targets in this tumor.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0191-z.
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Methods Cell lines. Kelly and BE2C neuroblastoma cell lines were obtained from the American Type Culture Collection (BE2C) and DSMZ (Kelly). All cell lines used for the genome-scale CRISPR-Cas9 screen have been previously described 7 . All cell lines were short tandem repeat (STR) tested for identity. Neuroblastoma cell lines were cultured in RPMI media containing 10% fetal bovine serum and 1% penicillin-streptomycin and validated to be free of Mycoplasma species.
In vivo tumor models. We adhered to animal protocols approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. Animals were maintained according to institutional guidelines. Eight-week-old female nude mice were subcutaneously implanted with 1 × 10 6 BE2C cells in 30% matrigel/ PBS. Mice were assigned to four groups: vehicle, JQ1, THZ1, or the combination of JQ1 and THZ1. Treatment with small-molecule inhibitors was initiated once tumors engrafted and reached 100-150 mm 3 . Compounds were solubilized in 10% DMSO and 90% 5% dextrose in water. JQ1 was delivered at 50 mg kg −1 daily by intraperitoneal injection, and THZ1 was delivered at 10 mg kg −1 twice daily by intraperitoneal injection. Mice were treated for 14 d and followed for survival. Tumors were measured by calipers twice weekly. Mice were weighed twice a week. Animals were euthanized according to institutional guidelines when tumors reached 2,000 mm in length or width or if animals became moribund. Dependency scores were generated for each gene in each cell line using the CERES algorithm 7 . Briefly, CERES is a computational method to estimate gene dependency levels from CRISPR-Cas9 essentiality screens while accounting for the copy-number-specific effect, as well as variable single guide RNA activity. The gene dependency scores generated by CERES are absolute dependency scores with each cell line scaled to have an average dependency score of 0 for negative control single guide RNAs and an average dependency score of − 1 for a set of positive control core essential genes.
CRISPR-
To generate a list of selective dependencies in MYCN-amplified neuroblastoma, the CERES data were mean centered for each gene. The genes were then selected as dependencies if they had more than 2 MYCN-amplified neuroblastoma lines that scored below 4 s.d. from the mean, 3 lines that scored below 3 s.d. from the mean, or were enriched for dependency below a threshold of 2 s.d. from the mean using the Kolmogorov-Smirnov test with a false discovery rate less than 0.05 using multiple testing correction of the empiric P values. Candidate dependencies were filtered to only include those that also had an absolute dependency effect before the mean centering described above. Genes that had overall negative scores across all cancer lines in the screen were considered to be consistent with pan-essentials and were excluded. Candidate dependency genes were further filtered to include those with expression in MYCN-amplified neuroblastoma in the Cancer Cell Line Encyclopedia 40 . Thus, final scores reflect selective dependencies relative to findings with all other tumor types in the screen.
Gene ontology classification. Gene ontologies were assigned using the Gene Ontology subset (GO-slim) molecular function ontologies. These 42 GO-slim molecular functions were combined to create broader classifications of genes such as transcription factor activity or binding ( Supplementary Table 4 ). In each class of ontologies, a gene was counted only once for membership to any of the defining ontologies. A Fisher's exact test was performed to look for enrichment in the set of 147 dependency genes or 77 super-enhancer associated genes versus the genome as a whole. P values were adjusted using the Benjamini-Hochberg multiple testing correction. qPCR. Total RNA was harvested using Trizol (Life Technologies) according to the manufacturer's protocol. First-strand synthesis was performed with Superscript III (Invitrogen). qPCR analysis was conducted on the Vii7 system (Life Technologies) with SYBR Green PCR Master Mix (Roche) using validated primers specific to each target gene. Primer sequences are displayed in Supplementary Table 5 .
Microarray analysis. BE2C cells grown in 6-well plates were treated with JQ1 (3 µ M) and THZ1 (125 nM) and collected at 0, 1, 4, and 12 h with Trizol (Life Technologies). External RNA Control Consortium spike-in RNA was added directly to Trizol before RNA extraction as previously described 41 . Samples were prepared using the 3′ IVT assay (Affymetrix) and labeled by biotinylation.
Following labeling, biotinylated antisense RNA was hybridized to the PrimeView Human 3′ GeneChips for 16 h at 45 °C in an Affymetrix Hybridization Oven 645. Arrays were washed and stained in the Affymetrix Fluidics Station 450 using the GeneChip Hybridization, Wash, and Stain Kit. The arrays were scanned on GeneChip Scanner 3000 7G. For further details of data analysis, refer to the Supplementary Note.
Western blotting. Whole-cell lysates were prepared in Buffer C as previously described 23 . Equivalent amounts of protein were separated by SDS-PAGE and blocked by standard methodologies. Immunoblotting was carried out with the following antibodies: PHOX2B-B11X (Santa Cruz Biotechnology), ISL1 clone 39.4D5 (Developmental Hybridoma Studies Bank), HAND2-A12X (Santa Cruz Biotechnology), GATA3 (Pierce Technologies), TBX2 (Abcam), cleaved caspase-3, and PARP1 (Cell Signaling Technology). β -actin (Cell Signaling Technology) was used to confirm equal loading. Secondary horseradish peroxidase-linked IgG antibodies to mouse or rabbit were from Cell Signaling Technology. Enhanced chemiluminescence agents were Pico and Femto ECL (Thermo-Fisher Scientific) and used according to the manufacturer's instructions. All data displayed are representative of at least three independent protein lysates and blots. siRNA knockdown. Control and target siRNAs were purchased from Dharmacon (GE Biosciences). Cells were subjected to 100 nM concentrations of siRNA in OPTIMEM-I (Gibco) for 6 h using lipofectamine 2000 (Invitrogen) as previously reported 42 . Knockdown was confirmed by western blotting at 24-48 h posttransfection, and RNA was extracted at the time of maximal protein knockdown. Two independent single siRNA oligonucleotides were utilized per gene assayed, and all experiments were completed at least in triplicate.
Colony formation assay. Cells were transfected with siRNAs as described. After treatment, cells were replated at 500 cells per well in 6-well dishes and grown in regular growth media for 10 d before 100% methanol fixation, 0.05% crystal violet staining, and subsequent quantitation. Experiments were completed in triplicate; data shown are the average of three independent experiments. ATAC-seq. ATAC-seq was performed as previously described 43 . Briefly, Kelly and BE2C cells were cultured under standard conditions and 50,000 cells were trypsinized and washed twice with PBS. The Tn5 transposition reaction was performed with the Nextera kit (Illumina) according to the manufacturer's protocol. Transposed DNA was then purified using the MinElute kit (QIAgen). Library amplification was performed using NEBNext High-Fidelity 2X PCR Master Mix (NEB), with SYBR Green I dye (Invitrogen) and Nextera primers Ad1 and Ad2.[x] at 25 µ M. Amplified libraries were purified with the PCR purification kit (QIAgen), and quality control was performed using the 2200 Tapestation (Agilent). Sequencing was performed with Illumina NextSeq 500 paired-end 75-bp reads.
Genome-wide occupancy analysis. ChIP-seq was performed as previously described 22, 23 . The following antibodies were used for ChIP: GATA3 (Thermo Fisher MA1028), HAND2 (Santa Cruz sc9409X), ISL1 (Developmental Hybridoma Studies Bank 40.3A4), MYCN (Invitrogen Biotechnology, MA-1-16638), PHOX2B (Santa Cruz sc376997X), TBX2 (Abcam ab33298), and H3K27ac (Abcam ab4729). Details of ChIP protocols and analysis, as well as super-enhancer identification and assignment, are found in the Supplementary Note.
Synergy studies and pharmacologic inhibitors. Synergy screening was performed with THZ1 synthesized by the Gray Laboratory (Dana-Farber Cancer Institute) and JQ1 synthesized by the Bradner Laboratory (Dana-Farber Cancer Institute). Experiments were validated with compounds from commercially available sources: JQ1 (Sigma-Aldrich) and THZ1 (EMD Millipore). For assessment of synergy, neuroblastoma cell lines were plated in 384-well tissue culture-treated plates at a density of 25,000 cells ml −1 . Cells were then treated with single or combinations of compounds and subsequently analyzed for cell viability on days 0, 1, and 3 using the Cell-TiterGlo luminescent assay kit (Promega) per the manufacturer's instructions. Luminescence was read on a Fluostar Omega Reader (BMG Labtech). For cell growth assays and gene expression studies, JQ1 was used at 3 μ M and THZ1 at 78 nM (Kelly) or 125 nM (BE2C), with DMSO as a vehicle control. Synergy was assessed by the Chou-Talalay Combination index, isobologram, and excess over Bliss methods 38 .
Statistical analysis. Data from the ChIP-seq and CRISPR-Cas9 screens were analyzed as described above. Animal experiments were analyzed by two-sided analysis of variance (ANOVA) for tumor volume and weight means, and by the logrank test for survival. Other data were analyzed with one-or two-sided ANOVA with post hoc Tukey tests, two-sided t-tests, or one-or two-sided Fisher exact tests as appropriate for multiple or pair wise comparisons. Statistical significance was defined as a P < 0.05. Data were analyzed with GraphPad Prism 7.01, and all error bars represent standard deviation unless otherwise noted.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Code availability. Custom code written in R/python to perform analyses of CRISPR-Cas9 and ChIP-seq data is available upon reasonable request. Data availability. Gene dependency scores from the CRISPR-Cas9 screen are publicly available at https://doi.org/10.6084/m9.figshare.5520160.v1 7, 44 . ChIP-seq (GSE94822), ATAC-seq (GSE94823), and spike-in microarray (GSE108914) data are available through GEO; for further details, see Supplementary Table 6 .
Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity. For cellular and molecular assays, sample sizes were chosen based on expected phenotypes and previous experience with assay variability. Results from genome-scale CRISPR assays inferred strong phenotypic effects resulting from the disruption of essential genes and thus 3-6 technical replicates were chosen for most experiments. For colony formation, immunoblotting, qRT-PCR and drug treatment assays, experiments were completed at least in triplicate biological replicates. Technical replicates representing the same cells assayed at the same time were limited and not included in the total n value. N values denoted in the figure legends represent independent biological replicates. ChIP-seq experimental design is detailed in ChIP-seq reporting summary. CRISPR-Cas9 experiments for genome-scale analysis were completed using 70,000 guides and an average of 4 guides per gene. The CRISPR sgRNA library contains 1000 non-targeting guides as negative controls. Animal experiments were completed with a total of 8 animals per treatment group.
Data exclusions
Describe any data exclusions. Outlier analysis for qRT-PCR studies were performed and values representing greater than or less than 3 standard deviations from the mean were excluded. No data exclusions were performed for other assays. For CRISPR-Cas9 experiments, a pool of guides was transduced into a population of cells, and cells were cultured for approximately 21 days in vitro. At the end of the assay, barcodes for each guide were sequenced for each cell line in replicate. Reads per kilobase were calculated for each replicate and then the log2 fold change compared to the initial plasmid pool was calculated for each guide. Samples with poor replicate reproducibility, as well as guides that have low representation in the initial plasmid pool, were removed from analysis. In total, each gene was assayed with, on average, 4 guides per gene.
Replication
Describe whether the experimental findings were reliably reproduced. Experimental findings were reliably reproduced by multiple independent individuals. For example, combination JQ1+THZ1 experiments for cDNA expression analysis as well as effects on cell growth were replicated independently by three individuals at distinct timepoints. CRISPR-Cas9 screeening was validated by low throughput siRNA analysis ( Figure 1E ,F).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Experimental groups were defined based on appropriate biological and technical controls. Groups of animals were subcutaneously implanted with 1x10^6 BE2C cells the right flank of 7-8 week old nude female mice. Treatment was started when tumors reached 100-150mm3 with rolling admission into all 4 groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Whole genome ChIP-seq analysis was confirmed by two individuals blinded to the identity of the proteins involved. CRISPR-cas9 screening was performed by blinded screening -individuals involved in the screening were aware of the cell line used for screening but not final results of sequencing. Cell growth and expression analysis could not be blinded effectively, however, were reproduced by multiple investigators. Xenograft experiments were not blinded to drug identity.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study. CERES ( For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission. c. Report whether the cell lines were tested for mycoplasma contamination.
All cells were routinely tested for mycoplasma and confirmed negative.
d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified lines listed in the ICLAC database were used in this study.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Eight-week old female nude mice were obtained from Charles River Laboratories and subcutaneously xengrafted with 1x10^6 BE2C cells in 30% matrigel/PBS. Animals were treated with IP injection of compound as detailed in the manuscript once tumors engrafted and reached 100-150mm3. Mice were sacrificed when tumors reached a maximum of 2000 mm in length or width or if they became moribund per institutional policies.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
This study did not involve human research participants.
